No abstract

Summary:The objective of this study is to investigate the outcome of children 24 months of age or younger (infants) at the time of allogeneic bone marrow transplantation (BMT) for acute leukemia or myelodysplasia. We analyzed the survival rate, prognostic factors, incidences of late sequelae, and immune reconstitution in 22 infants who underwent allogeneic BMT. The 5-year event-free survival estimate was 45.5% (95% confidence interval (CI), 24.4% to 63.3%). Six patients died of transplant-related complications and six died of disease relapse. Remission status at the time of BMT was the most important prognostic factor (P ‫؍‬ 0.005): no patient who received a transplant while their disease was not in remission survived, whereas the 5-year survival estimate for infants who underwent BMT during remission was 56% (95% CI, 31% to 75%). Long-term outcomes in the 10 infant survivors were compared with those of 10 older controls matched for diagnosis, disease status at the time of BMT, calendar year at the time of BMT, and source of stem cells. Immune function 1 year after transplantation and the incidences and spectra of late sequelae were similar for both groups during a median of 3.5 years (range, 1.5 to 7.2 years) of follow-up. Bone Marrow Transplantation (2001) 27, 717-722. Keywords: allogeneic transplantation; infant leukemia; myelodysplastic syndrome; late sequelaeThe incidences of lymphoid and myeloid leukemias in infants are approximately equal. Acute lymphoblastic leukemia (ALL) in infants accounts for 2.5% to 5% of all cases of childhood ALL, and acute myeloid leukemia (AML) in infants accounts for 6% to 14% of all cases of childhood AML. 1 The frequent presence of poor prognostic factors such as 11q23/MLL rearrangement in ALL and a high leukocyte count at the time of diagnosis of AML results in an overall long-term survival of only approxiCorrespondence: WH Leung,

No abstract

No abstract

A new broad-spectrum anthelminthic, anti minth (pyrantel pamoate), has been evaluated in 1,506 patients, mainly children. Single doses of 5/mg/lb/body weight (base activity) showed high overall efficacy against Enterobius vermicularis (97.2%) and Ascaris lumbricoides (97.5%). In tropical locations, in patients with multiple in festataons, single doses of 10 mg/lb/day for three consecutive days achieved a cure rate of 86.4 per cent with Necator americanus. With a smaller number of patients, a lower dosage of 5 mg/lb/day for three consecutive days was also effective (90.7%). At recommended doses (5 mg/lb/day), Antiminth (pyrantel pamoate) was well tolerated and free of adverse effects upon hematologic, renal, and hepatic function. There was not the troublesome staining seen with certain other anthelminthics. The safety profile was further substantiated by clinical experience with doses in excess of 5 mg/lb/body weight, at times carried on for several weeks.